TLDR New treatments like JAK inhibitors offer hope for better alopecia areata management.
The article discusses the treatment of alopecia areata (AA), an autoimmune condition causing hair loss, traditionally managed with corticosteroids that have limited efficacy and adverse effects. Recently, janus kinase inhibitors (JAKIs) like baricitinib and ritlecitinib have been approved, offering new hope for AA treatment. These agents, along with other emerging therapies such as monoclonal antibodies and targeted immune modulators, could change current treatment protocols. However, a better understanding of their adverse drug events is necessary, as ongoing trials continue to investigate these aspects.
57 citations
,
August 2023 in “American Journal of Clinical Dermatology” JAK inhibitors and platelet-rich plasma show promise for treating alopecia areata.
148 citations
,
March 2022 in “The New England Journal of Medicine” Baricitinib was effective in treating alopecia areata in two major trials.
290 citations
,
August 2021 in “Clinical Reviews in Allergy & Immunology” JAK inhibitors show promise for treating alopecia areata, but more research is needed.
138 citations
,
March 2021 in “Journal of the American Academy of Dermatology” Ritlecitinib and brepocitinib effectively regrow hair in alopecia areata patients.
56 citations
,
January 2021 in “Clinical and Experimental Medicine” The document concludes that while there are various treatments for Alopecia Areata, there is no cure, and individualized treatment plans are essential due to varying effectiveness.
56 citations
,
January 2019 in “Lancet” JAK inhibitors help regrow hair in alopecia areata patients, improving their quality of life.
205 citations
,
April 2013 in “British Journal of Dermatology” Platelet-rich plasma treatment significantly increased hair regrowth and decreased discomfort in alopecia patients, making it a potentially better and safer treatment option.
April 2019 in “International journal of research in dermatology” A child with rough nails also had hair loss and allergies.